Annual Review | Dr. Guiqiang Wang: Pursuing Clinical Cure for Hepatitis B, Focusing on Advances in New Drug Development

Antiviral therapy is the primary treatment strategy for chronic hepatitis B (CHB), aiming to inhibit HBV replication, alleviate liver cell inflammation and fibrosis, and reduce the risk of liver failure, decompensated cirrhosis, and hepatocellular carcinoma (HCC). However, there is currently no treatment that can completely clear covalently closed circular DNA (cccDNA) in infected liver cells, which is a major obstacle to achieving clinical cure for CHB. In recent years, with the continuous development and clinical trials of new drugs targeting different points, exploration of new treatment strategies for the clinical cure of CHB is gradually progressing. To this end, this journal invited Dr. Guiqiang Wang from the Department of Infectious Diseases at Peking University First Hospital to share the latest developments in the field of new drug development for the clinical cure of CHB over the past year.
Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

The "Hepatology Digest - Liver Vascular Disease Column" is an academic column initiated by Dr. Qixing Shun from the Department of Gastroenterology, Northern Theater General Hospital, in response to the invitation of the editorial department of "Hepatology Digest". It regularly collects and organizes research progress in the field of hepatic vascular diseases. Every two weeks (Wednesday), an important literature is selected for in-depth discussion, aiming to help readers understand the rationale behind clinical research, inspiring clinical and scientific thinking.